News
Reported Earlier, BrainStorm Cell Therapeutics Announces Management Changes As It Plans Registrational Phase 3b Trial Of NurOwn
17 Apr 24
News
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
11 Apr 24
Government, News, Regulations, SEC
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
9 Apr 24
Movers
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
9 Apr 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Brainstorm Cell Q4 EPS $(0.11) Beats $(0.15) Estimate
1 Apr 24
Earnings, Earnings Beats, News
12 Health Care Stocks Moving In Monday's Intraday Session
1 Apr 24
Movers
Brainstorm Cell: Q4 Earnings Insights
1 Apr 24
Earnings
12 Health Care Stocks Moving In Monday's After-Market Session
25 Mar 24
Movers
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Wednesday's Intraday Session
20 Mar 24
Movers
Brainstorm Cell Therapeutics Has Been Granted Israeli Patent Number 277447 Titled "Cell-Type Specific Exosomes And Use Thereof (For The Treatment Of Neurodegenerative Diseases)"
5 Mar 24
Biotech, News, General
Brainstorm Cell Therapeutics Will Present A Poster Outlining The Proposed Design For A Phase 3B Trial Of Nurown In Amyotrophic Lateral Sclerosis At The MDA Clinical And Scientific Conference, On Monday
27 Feb 24
Biotech, News, Health Care, General
12 Health Care Stocks Moving In Wednesday's After-Market Session
21 Feb 24
Movers
12 Health Care Stocks Moving In Monday's Pre-Market Session
19 Feb 24
Movers
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
30 Jan 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Press releases
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
16 Apr 24
Small Cap, Press Releases
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
11 Apr 24
Small Cap, Press Releases
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
10 Apr 24
Small Cap, Press Releases
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
9 Apr 24
Press Releases
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
8 Apr 24
Small Cap, Press Releases
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
1 Apr 24
Earnings, Press Releases
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
27 Feb 24
Press Releases
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
23 Feb 24
Small Cap, Press Releases
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
13 Feb 24
Press Releases